Panorama Research Institute and Regenerative Sciences Institute, 1230 Bordeaux Drive, Sunnyvale, CA 94089, USA.
Rejuvenation Res. 2011 Aug;14(4):437-41. doi: 10.1089/rej.2011.1238.
Mammalian target of rapamycin (mTOR), a serine/threonine kinase and component of the mTORC1 signaling complex, acts as an energy, nutrient, growth factor, stress, and redox sensor to increase protein synthesis and decrease macroautophagy. mTORC1 plays a central role in the maintenance of homeostasis and its deterioration, seen in aging. The Food and Drug Administration (FDA)-approved immunosuppressive macrolide rapamycin binds immunophilin FKBP12 (FK506-binding protein) to inhibit mTORC1. Unlike most other interventions tested to date, inhibition of mTORC1 by rapamycin extends life span in old mice, likely by a combination of increased autophagy and decreased mRNA translation. Hutchinson-Gilford progeria syndrome (HGPS) is a lethal genetic disorder affecting children that is characterized by symptoms of premature aging, such as atherosclerosis. Increased autophagy induced by rapamycin reduces accumulation of progerin, an alternate spliced form of lamin A/C, that forms insoluble toxic aggregates, resulting in reduced HGPS-associated nuclear blebbing, growth inhibition, epigenetic dysregulation, and genomic instability. Rapamycin-induced autophagy also suppresses symptoms in mouse models of Alzheimer, Parkinson, and Huntington diseases, where toxic insoluble protein aggregates accumulate. On the basis of these results, modulation of mTORC1 function is a promising target for the development of therapeutics for neurodegenerative diseases and HGPS. Rapamycin is the obvious candidate for near-term evaluation in the treatment of these diseases. However, the substantial set of rapamycin-associated adverse effects, as well as the lack of aging-specific human data, should caution the routine use of rapamycin as an antiaging agent. The use of safer, but perhaps weaker, indirect mTORC1 inhibitors, such as metformin and resveratrol, may prove useful. Further study will ascertain whether such compounds extend human health or life span.
哺乳动物雷帕霉素靶蛋白(mTOR)是一种丝氨酸/苏氨酸激酶,也是 mTORC1 信号复合物的组成部分,它作为能量、营养、生长因子、应激和氧化还原传感器,增加蛋白质合成,减少巨自噬。mTORC1 在维持体内平衡及其恶化中发挥核心作用,在衰老中可见。美国食品和药物管理局(FDA)批准的免疫抑制大环内酯类雷帕霉素与免疫亲和素 FKBP12(FK506 结合蛋白)结合,抑制 mTORC1。与迄今为止测试的大多数其他干预措施不同,雷帕霉素抑制 mTORC1 可延长老年小鼠的寿命,这可能是通过增加自噬和减少 mRNA 翻译的组合实现的。Hutchinson-Gilford 早衰综合征(HGPS)是一种影响儿童的致命遗传性疾病,其特征是过早衰老的症状,如动脉粥样硬化。雷帕霉素诱导的自噬增加可减少异常剪接形式的 lamin A/C 即 progerin 的积累,progerin 形成不溶性有毒聚集体,导致 HGPS 相关核泡状化减少、生长抑制、表观遗传失调和基因组不稳定减少。雷帕霉素诱导的自噬也可抑制阿尔茨海默病、帕金森病和亨廷顿病小鼠模型中的症状,这些疾病中有毒的不溶性蛋白聚集体积累。基于这些结果,调节 mTORC1 功能是开发神经退行性疾病和 HGPS 治疗方法的有希望的靶点。雷帕霉素是治疗这些疾病的近期评估的明显候选药物。然而,雷帕霉素相关的大量不良作用,以及缺乏针对衰老的人类数据,应该谨慎将雷帕霉素常规用作抗衰老剂。使用更安全但可能较弱的间接 mTORC1 抑制剂,如二甲双胍和白藜芦醇,可能会证明是有用的。进一步的研究将确定这些化合物是否延长人类的健康或寿命。